

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation
金斯瑞生物科技股份有限公司*

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1548)

VOLUNTARY ANNOUNCEMENT

RECEIVED THE PERSON OF THE YEAR AWARD

This is a voluntary announcement made by Genscript Biotech Corporation (the “**Company**” together with its subsidiaries, the “**Group**”).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on 14 November 2018, Dr. Zhang Fangliang, the Chairman and Chief Executive Officer of the Company (“**Dr. Zhang**”), was awarded as the “Person of the Year” at the China Healthcare Summit 2018 jointly organized by BioCentury and BayHelix in Shanghai, China.

The China Healthcare Summit has been held for five consecutive years. It aims to promote the formation of a modern healthcare ecosystem in China and recognize leading Chinese figures who have made remarkable contributions as well as representative Chinese companies, major transactions and research and development achievements that have brought significant impact to the life and healthcare field. The “Person of the Year” award recognizes an outstanding individual whose contributions have changed the landscape, reputation, and ecosystem for drug and/or MedTech research and development, deal transactions, and/or commercialization etc. in China, according to the website of BioCentury.

The Board is delighted that Dr. Zhang had received such honour and will continue to strive to provide its customers with platforms for technology development and high quality life sciences services and products with due diligence and professionalism.

Dr. Zhang would like to express his cordial appreciation for all customers, partners, shareholders, investors, and colleagues for their long-term trust and support that had driven the continuous growth and expansion of the Company since its inception.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.

By order of the Board
Genscript Biotech Corporation
Zhang Fangliang
Chairman and Chief Executive Officer

Hong Kong, 14 November 2018

As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Ms. Wang Ye and Mr. Meng Jiange; the non-executive Directors are Dr. Wang Luquan and Mr. Pan Yuexin; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Ms. Zhang Min.

* *For identification purposes only*